Nancy S. Scher

543 total citations
8 papers, 419 citations indexed

About

Nancy S. Scher is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Nancy S. Scher has authored 8 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Nancy S. Scher's work include Radiopharmaceutical Chemistry and Applications (2 papers), Bone health and treatments (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). Nancy S. Scher is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (2 papers), Bone health and treatments (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). Nancy S. Scher collaborates with scholars based in United States, Switzerland and Israel. Nancy S. Scher's co-authors include Richard Pazdur, Amna Ibrahim, Rajeshwari Sridhara, Atiqur Rahman, Jogarao Gobburu, Ning Li, Grant Williams, Rebecca Wood, John Leighton and Brian Booth and has published in prestigious journals such as Blood, Clinical Cancer Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Nancy S. Scher

8 papers receiving 408 citations

Peers

Countries citing papers authored by Nancy S. Scher

Since Specialization

Citations

This map shows the geographic impact of Nancy S. Scher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy S. Scher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy S. Scher more than expected).

Fields of papers citing papers by Nancy S. Scher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy S. Scher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy S. Scher. The network helps show where Nancy S. Scher may publish in the future.

Co-authorship network of co-authors of Nancy S. Scher

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy S. Scher. A scholar is included among the top collaborators of Nancy S. Scher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy S. Scher. Nancy S. Scher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer 2018 ·Clinical Cancer Research ·Lynn Howie, Nancy S. Scher, Laleh Amiri‐Kordestani, Lijun Zhang, Bellinda L. King‐Kallimanis, (unknown), (unknown), Kirsten B. Goldberg, Paul G. Kluetz, Amna Ibrahim, Rajeshwari Sridhara, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver	50
2	First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer 2013 ·Clinical Cancer Research ·Gideon M. Blumenthal, Nancy S. Scher, Patricia Cortazar, Somesh Chattopadhyay, Shenghui Tang, Pengfei Song, Qi Liu, (unknown), Anne M. Pilaro, Amy Tilley, Kathryn E. King, Laurie Graham, Barbara L. Rellahan, Wendy C. Weinberg, Bo Chi, Colleen J. Thomas, P. E. Hughes, Amna Ibrahim, Robert Justice, Richard Pazdur	89
3	End points to establish the efficacy of new agents in the treatment of acute leukemia 2006 ·Blood ·Frederick R. Appelbaum, Daniel Rosenblum, R.J. Arceci, William L. Carroll, Philip P. Breitfeld, Stephen J. Forman, Richard A. Larson, Stephanie J. Lee, Sharon B. Murphy, Susan O’Brien, Jerald P. Radich, Nancy S. Scher, Franklin O. Smith, Richard M. Stone, Martin S. Tallman	69
4	Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. 2003 ·PubMed ·Amna Ibrahim, Nancy S. Scher, Grant Williams, Rajeshwari Sridhara, Ning Li, Gang Chen, John Leighton, Brian Booth, Jogarao Gobburu, Atiqur Rahman, (unknown), Rebecca Wood, (unknown), Richard Pazdur	157
5	A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastases 2003 ·Clinical Pharmacology & Therapeutics ·B Booth, Atiqur Rahman, Amna Ibrahim, Nancy S. Scher, (unknown), Horst Schran, Peiming Ma, (unknown), Jogarao Gobburu	3
6	U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid 2002 ·The Oncologist ·Martin H. Cohen, Ramzi Dagher, Donna Griebel, Amna Ibrahim, Alison Martin, Nancy S. Scher, Gerald H. Sokol, Grant A. Williams, Richard Pazdur	42
7	Absence in Human Ejaculate of Cephalexin Following its Oral Administration 1979 ·International Journal of Andrology ·(unknown), Nancy S. Scher, (unknown), (unknown), E Eylan	1
8	Cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in normal and chronic lymphocytic leukemia lymphocytes. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Nancy S. Scher, Franco Quagliata, V. G. Malathi, (unknown), (unknown), R Silber	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact